Novartis bolsters innovative dermatology portfolio through acquisition of ziarco group limited eczema child face

16 December 2016 Novartis announced today that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. Varicose eczema images This acquisition would add a once-daily oral H4 receptor antagonist in development for atopic dermatitis (AD), commonly known as eczema, to complement the growing Novartis dermatology portfolio and pipeline. How to get eczema under control The transaction is subject to customary closing conditions, including regulatory approval.

What causes dermatitis in adults The financial details of this transaction are not disclosed.

Ziarco’s lead investigational product, ZPL389, is a potential first-in-class oral treatment for moderate-to-severe eczema. Causes eczema in babies Eczema is a chronic, itchy, inflammatory skin condition found in millions of children and adults worldwide[1]. How to relieve eczema on face In addition, it is associated with sleep loss and a significant reduction in quality of life[2]. Eczema feet pictures Currently, no safe, effective, and well-tolerated oral treatments are available for the moderate-to-severe form of this condition.

“There is an unmet need for innovative, effective and safe oral treatment options for people living with eczema,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. How to treat eczema on feet “We are proud of our dermatology capabilities shown by the recent successful launches of Cosentyx and Xolair. Chronic eczema in adults Now we’re excited about a potential new medicine for people with eczema through the acquisition of Ziarco and the addition of a first-in-class oral H4 receptor antagonist to our growing pipeline.”

In a proof of concept study, ZPL389 showed a clinically and statistically significant reduction of eczema. Ways to treat eczema at home After eight weeks of treatment, the compound reduced the Eczema Area and Severity Index (EASI) score by 50% (placebo: 27%, (p=0.01)) in a study of 98 patients. Alternative therapies for eczema In addition, there was a statistically significant improvement in SCORing Atopic Dermatitis (SCORAD) and body surface area (BSA) scores affected by eczema for ZPL389. Possible causes of eczema The study also showed a decrease in itching, which was numerically greater in the active treatment arm. National eczema day Both the EASI and SCORAD sub-scores related to itching showed positive results and there was a statistically significant decrease in sleep loss for the active comparator. Eczema atopic dermatitis natural treatment Itch is a major cause for sleep loss in eczema patients[2]. Severe eczema on hands In clinical studies conducted to date, ZPL389 has a favorable safety profile.

Eczema poses a significant burden on health-care resources and patients’ quality of life with recent data showing that its prevalence is still increasing[3]. Eczema skin disease treatment Eczema affects up to 10% of the population in the US alone[4],[5], with approximately 15% of children and 70% of adults having the moderate-to-severe form of the disease[6]. Eczema on feet pics Treatment does not cure eczema but can control symptoms and potentially improve quality of life[7].

Novartis is committed to addressing the unmet medical needs of patients living with dermatological conditions and improving their overall quality of life by providing innovative medicines. What is eczema disease The Novartis Dermatology portfolio includes Cosentyx (secukinumab) for the treatment of moderate-to-severe psoriasis and Xolair (omalizumab) for the treatment of chronic spontaneous urticaria.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Infected eczema pictures Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Eczema allergy medication Novartis is the only global company with leading positions in these areas. How to eczema is treated In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Eyelid eczema treatment Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Eczema around eyes pictures Novartis products are available in more than 180 countries around the world.

4. Severe dermatitis pictures Silverberg et al. Photos of eczema on the face Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. National eczema association J Allergy Clin Immunol. How to treat mild eczema on face 2013; 132 (5): 1132-1138.

5. Eczema baby back Shaw TE, Currie GP, Koudelka CW, Simpson EL. Mild eczema on face Eczema Prevalence in the United States: Data from the 2003 National Survey of Children’s Health. Nummular eczema toddler J. Eczema rash on neck Invest. Varicose eczema patient uk Dermatol. Wiki eczema 2001; 131:67-73.

7. Pictures eczema toddlers American Academy of Dermatology (AAD) website. Eczema toddler Atopic Dermatitis. Eczema organic treatment Available at: Eczema skin rash Last accessed December 2016